Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.

The initiative is designed to support breakthrough scientific discovery with the potential to advance human health and accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.

Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.

• Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in Asia
• System strengthens Taiwan’s capabilities in protein drug discovery research

Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies

LONDON, UK  – January 7, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.